Safety and effectiveness of Holmium Laser enucleation of the prostate in patients on ongoing oral antiplatelet therapy

Safety and effectiveness of Holmium Laser enucleation of the prostate in patients on ongoing oral antiplatelet therapy - Safety and effectiveness of Holmium Laser enucleation of the prostate in patients on ongoing oral antiplatelet therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002734

Enrollment

Registered

2009-11-10

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hypertrophy

Interventions

Patient on ongoing antiplatelet therapy Patient without oral antiplatelet trapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients suffering from lower urinary tract symptom secondary to BPH.

Exclusion criteria

Exclusion criteria: 1) Anesthesiologists (ASA) score of 4 or higher 2) Prostate cancer daignosed before HoLEP

Design outcomes

Primary

Measure	Time frame
Persitent bleeding required cauterization of bleeders within 7 days after surgery	—

Secondary

Measure	Time frame
1)Blood transfusion 2)Postoperative decrease of Hb 3)IPSS, Qmax, PVR	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026